Norway
· Delayed Price · Currency is NOK Photocure ASA Company Description
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States.
It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions.
The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology.
It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners.
Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
| Country | Norway |
| Founded | 1993 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Daniel Schneider |
Contact Details
Address: Hoffsveien 4 Oslo, 0275 Norway | |
| Phone | 47 22 06 22 10 |
| Website | photocure.com |
Stock Details
| Ticker Symbol | PHO |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010000045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Schneider | Chief Executive Officer |
| Erik Dahl | Chief Financial Officer |
| David Moskowitz | Head of Investor Relations |